Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy
Nephrology Dialysis Transplantation · 31.03.2026 · 41 (4) · 786-792
DOI: 10.1093/ndt/gfaf210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.10.2025. Verfasst von Ran Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Proteinuria, Vasculitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Key Project of Jiangxi Provincial Nature Science Foundation, Thousand Talents Plan, Project of Introducing and Training High-Level Talents of Innovation and Entrepreneurship in Jiangxi Province.
Abstract (Originalsprache)
Background
To investigate the efficacy and safety of telitacicept in adult immunoglobulin A vasculitis nephritis (IgAVN) patients with persistent proteinuria.
Methods
This prospective single-arm study enrolled patients aged ≥18 years diagnosed with IgAVN, an estimated glomerular filtration rate >60 mL/min/1.73 m2, previously received previous treatment with corticosteroids and immunosuppressants or had contraindications to the use of corticosteroids and immunosuppressants, and a 24-h urinary protein–creatinine ratio (UPCR) >1 g/g. Patients received telitacicept 160 mg weekly for 6 months.
Results
A total of 13 patients were enrolled in this study, of which 7 were males. The mean age of patients was 35 years. The mean time since diagnosis before telitacicept treatment was 12.6 months. After 6 months of treatment with telitacicept, the mean 24-h UPCR decreased from a baseline value of 2.9 ± 0.8 to 0.5 ± 0.3 g/g (P < .001). At 9 months, 12 patients (92.3%) achieved complete remission, and the mean 24-h UPCR decreased to 0.4 ± 0.1 g/g. Additionally, the renal function of patients remained stable, urinary red blood cells, blood CD4+ T cells, CD19+ B cells, immunoglobulin levels were decreased compared with the baseline values in all patients at 9 months (P < .05). No severe adverse events were observed.
Conclusion
Additional telitacicept significantly increased the complete remission rate of IgAVN with persistent proteinuria and stabilized renal function, without serious adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China.
- Department of Nephrology, Ganzhou People's Hospital, Ganzhou, P. R. China.
- Department of Pediatrics, Gaoxin Branch of the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
Förderung
- Key Project of Jiangxi Provincial Nature Science Foundation
- Thousand Talents Plan
- Project of Introducing and Training High-Level Talents of Innovation and Entrepreneurship in Jiangxi Province
- Jiangxi Province Key Laboratory of Molecular Medicine
Zitieren
APA
Zhang, R., Yang, Y., Zeng, F., Liu, D., Cai, W., Wan, H., Cai, F., Tao, S., & Xu, G. (2026). Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy. Nephrology Dialysis Transplantation, 41(4), 786-792. https://doi.org/10.1093/ndt/gfaf210
Vancouver
Zhang R, Yang Y, Zeng F, Liu D, Cai W, Wan H, et al. Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy. Nephrology Dialysis Transplantation. 2026;41(4):786-792. doi:10.1093/ndt/gfaf210
BibTeX
@article{Zhang2026,
author = {Zhang, Ran and Yang, Yang and Zeng, Fang and Liu, Dehui and Cai, Wenbin and Wan, Hongping and Cai, Fen and Tao, Sansan and Xu, Gaosi},
title = {Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {4},
pages = {786--792},
doi = {10.1093/ndt/gfaf210}
}
EUVIMED